Fund moves

Biogen (BIIB): Artemis Investment Management LLP added to its stake +345K shares

Artemis Investment Management LLP added to its stake in Biogen, per its Q1 2026 13F.

572K
Shares reported · +345K vs prior quarter
1.1%
Disclosed portfolio weight
$105M
Reported value
Holdings as of
Mar 31, 2026
Filed
Apr 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 30, 2026CongressDisclosed purchase of BIIB — reported range $1,001 - $15,000
  2. Feb 12, 2026Insider · Their first buy on recordOfficer purchased ~$585 of BIIB shares in the open market
  3. Mar 11, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 11, 2026, Biogen Inc. (the “Company”) announced that Susan H. Alexander, Chief Legal Officer, will depart from the Company effective as of the end May, 2026.”
  4. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  5. Mar 27, 2026FDAFDA drug approval: Spinraza
  6. Mar 27, 2026CongressDisclosed purchase of BIIB — reported range $1,001 - $15,000
  7. Mar 31, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
  8. Apr 6, 2026Company filing · Form 8-K · ResultsReported its results

What came next

  1. Apr 29, 2026Company filing · Form 8-K · ResultsReported its results
  2. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  3. May 6, 20265% stakeFMR LLC reported a passive stake (13G) of 8.7%
  4. May 11, 2026Congress · 1 personMembers of Congress: 2 purchases
  5. May 12, 2026CongressDisclosed purchase of BIIB — reported range $1,001 - $15,000
  6. May 14, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and signed an important agreement (and 2 more items)“Pursuant to the Merger Agreement, on April 14, 2026, Purchaser commenced a tender offer (the “Offer”) to acquire any and all of the issued and outstanding Shares, in exchange for (i) $41.00 per Share, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the “Cash Amount”), plus (ii) one contractual, non-transferable contingent value right per Share (each, a “CVR”)…”
  7. Jun 2, 2026CongressDisclosed sale of BIIB — reported range $15,001 - $50,000
  8. Jun 5, 20265% stakeFMR LLC reported a passive stake (13G) of 11.3%
  9. Jun 5, 2026CongressDisclosed purchase of BIIB — reported range $1,001 - $15,000
  10. Jul 1, 2026Company filing · Form 8-K · ResultsReported its results
  11. Jul 23, 2026Government · Federal Register noticeAdvisory Committee; Peripheral and Central Nervous System Drugs Advisory Committee; Termination and Reestablishment
  12. Jul 29, 2026Company filing · Form 8-K · ResultsReported its results
  13. Aug 3, 2026InsiderDirector sold ~$121K of BIIB shares in the open market
  14. Aug 4, 2026InsiderDirector sold ~$119K of BIIB shares in the open market
  15. Aug 6, 20265% stakeFMR LLC reported a passive stake (13G) of 12.4%
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Biogen

For Biogen, OQRO holds 2 Congress trade reports dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BIIB page.

How this filing works

Explore the data

Common questions

What does this filing report about Biogen (BIIB) stock?

Artemis Investment Management LLP added to its stake in Biogen, per its Q1 2026 13F. Now 572K shares, $105M reported value, 1.1% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Mar 31, 2026. Filed: Apr 13, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Biogen recently?

For Biogen, OQRO holds 2 Congress trade reports dated in the last 90 days. They are listed on the BIIB page.

Does this mean BIIB stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Biogen

Everything OQRO holds on this company is on its BIIB page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data